Vigene Biosciences Partners with The Michael J. Fox Foundation to Distribute Alpha-synuclein Knockdown Viral Vectors for Parkinson's Disease Research

Thursday, November 9, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

ROCKVILLE, Md., Nov. 8, 2017 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral

vector production and development, today announced a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) for AAV repository and domestic production. Viral vectors to knockdown mouse or human alpha-synuclein (aSyn) will be
made available for purchase in early 2018.

"We are pleased to have taken this step to make critical Parkinson's disease research tools more accessible to the wider research community," stated Dr. Zairen Sun, Vigene's CEO, "We believe that a key way to accelerate therapeutic development for Parkinson's patients is to provide validated viral vectors, that will enable researchers to obtain quality data, so that they focus on understanding the mechanisms underlying Parkinson's disease."

"The Michael J. Fox Foundation drives tool development toward the greatest needs of the field to accelerate therapeutic development in Parkinson's," said Nicole Polinski, PhD, associate director of research programs at MJFF. "Our partnership with Vigene enables the distribution of key viral vectors targeting alpha-synuclein — a sticky protein that clumps in the brains of people with PD — to help deepen understanding of the mechanisms of Parkinson's and speed urgently needed breakthroughs."

About Vigene Biosciences

Vigene Biosciences, Inc is a leader in viral vector based gene delivery for both life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene offers AAV, lentivirus and adenovirus based products and custom services. Both research grade and cGMP grade AAV, lentiviral and adenoviral vectors are available.

Contact Information

Jeffrey Hung, Ph.D. 

Chief Commercial Officer

Vigene Biosciences

301-251-6638

[email protected]

View original content:http://www.prnewswire.com/news-releases/vigene-biosciences-partners-with-the-michael-j-fox-foundation-to-distribute-alpha-synuclein-knockdown-viral-vectors-for-parkinsons-disease-research-300552105.html

SOURCE Vigene Biosciences



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store